Recombinant Mouse CD93 protein (rFc Tag) (HPLC verified)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3116

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse CD93 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Mouse CD93 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90%, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse CD93 protein Ala23-Asn572 (Accession# O89103) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 17064
• Accession: O89103
• PredictedSize: 85.1 kDa
• SDS-PAGE: 110-120 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp) is a transmembrane glycoprotein consisting of 652 amino acids. CD93 can exist in two forms: soluble (sCD93) and membrane-bound (CD93). CD93 is expressed predominantly on endothelial cells, where it plays a key role in the promotion of angiogenesis in physiology and disease. CD93 is also highly expressed in tumor-associated blood vessels, and its presence is associated with poor prognosis, poor response to immunotherapy, immune cell infiltration, and high tumor, lymph node, and metastasis (TNM) stages in many cancer types. (PMID: 37443812) Targeting CD93-related signaling pathways in the tumor microenvironment may be a novel therapeutic strategy for tumor immunotherapy.

References:

1. Tossetta G, et al. Cells. 2023;12(13):1778.                                                               
2. Sun Y, et al. Sci Transl Med. 2021;13(604):eabc8922.                                              
3. Guo A, et al. Front Immunol. 2022;13:907182. 
4. Wu B,et al. Front Immunol. 2023;14:984816.